UPDATE: Stifel Downgrades Vertex (VRTX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) Phase II Data Preview - Jefferies
September 7, 2021 8:25 AM EDTJefferies analyst Michael Yee reiterated a Buy rating and $230.00 price target on Vertex (NASDAQ: VRTX) on the belief that expectations are low for the Phase II data for VX-147 for APOL1+ FSGS implying a positive risk reward opportunity.
The analyst stated "we see... More
Here are 4 Major Pharma Stocks That Were Downgraded by Morgan Stanley Today
September 7, 2021 6:06 AM EDTMorgan Stanley analyst Matthew Harrison has made a series of calls today in the banks pharma coverage.
Harrison downgraded Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), and Amgen (NASDAQ: AMGN) to Equal Weight from Overweight as he sees limited upside in the mid-term.
On JNJ, a price target of $187.00 per share has remained unchanged.
Our prior investment thesis was based on anticipated strong performance from all three business segments. While we continue to expect J&J to continue to deliver solid quarterly... More
UPDATE: Morgan Stanley Downgrades Vertex (VRTX) to Underweight
September 7, 2021 3:53 AM EDT(Updated - September 7, 2021 4:44 AM EDT)
Morgan Stanley analyst Matthew Harrison downgraded Vertex (NASDAQ: VRTX) from Equalweight to Underweight with a price target of $202.00.
The analyst comments "Competitive concern (despite the high bar for success) is likely to keep VRTX from appreciating... More
